Retatrutide Research & Trial Evidence

Summary

Retatrutide is an investigational triple agonist at the GIP, GLP-1 and glucagon receptors. Phase 2 trials reported the largest mean weight reductions published for a pharmacological agent to date, around 24% at 48 weeks at the highest dose. It is not approved anywhere and Phase 3 outcome and safety data is still accumulating.

Last reviewed 2026-09-01

What it is

Retatrutide (development code LY3437943) is a single synthetic peptide engineered to activate three metabolic receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.

It follows a clear pharmacological progression: single GLP-1 agonists in the 2000s, dual GIP/GLP-1 agonism from the late 2010s, and triple agonism entering clinical trials in 2021.

Fully synthetic, based on the GIP peptide backbone with modifications including a fatty diacid chain for albumin binding and once-weekly dosing.

Adding glucagon receptor activity introduces an energy-expenditure component to a class that previously worked mainly through appetite reduction — a mechanistically different lever.

How it works

In plain terms

Most weight-loss peptides work by reducing appetite. Retatrutide does that through two appetite pathways and adds a third that raises the rate at which the body uses energy and mobilises fat from the liver.

Technical detail

GLP-1 receptor activation slows gastric emptying and acts on hypothalamic and hindbrain appetite circuits while enhancing glucose-dependent insulin secretion. GIP receptor activation contributes additional insulinotropic effect and appears to modulate central appetite signalling and adipose tissue handling. Glucagon receptor activation increases hepatic fatty acid oxidation and total energy expenditure, and reduces hepatic fat, while its hyperglycaemic tendency is offset by the incretin components. The albumin-binding fatty acid moiety extends half-life to support weekly administration.

Pathways involved

GLP-1R: appetite suppression, delayed gastric emptying, glucose-dependent insulin release
GIPR: insulinotropic effect, central appetite and adipose signalling
GCGR: increased energy expenditure and hepatic fat oxidation
Albumin binding via fatty diacid for weekly pharmacokinetics

Current research

Laboratory research

Receptor binding and cellular cAMP assays established balanced potency across the three receptors, with the profile deliberately weighted to limit glucagon-driven hyperglycaemia.

Animal research

Rodent obesity models demonstrated greater weight and hepatic fat reduction than dual agonism at matched exposure, with energy expenditure increases attributable to the glucagon component.

Human research

The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 reported mean weight reduction of approximately 17.5% at 24 weeks and 24.2% at 48 weeks at the 12 mg dose, versus about 2% with placebo. A parallel Phase 2 trial in type 2 diabetes reported HbA1c reductions around 2 percentage points. A separate study reported large reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease. Phase 3 programmes covering obesity, diabetes, osteoarthritis-related outcomes and cardiovascular endpoints are ongoing.

Ongoing research

The TRIUMPH Phase 3 programme is the main source of forthcoming efficacy and safety data; long-term cardiovascular outcome data is not yet published.

What is being investigated

Body weight reduction in obesity (Phase 2 and 3)
Glycaemic control in type 2 diabetes
Hepatic fat content in steatotic liver disease
Energy expenditure via glucagon receptor activity
Knee osteoarthritis outcomes in participants with obesity

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Not approved by any regulator; all use outside a registered trial is unapproved
Gastrointestinal adverse events — nausea, vomiting, diarrhoea, constipation — were the most common in Phase 2 and were dose-related
Dose-dependent heart rate increases were observed, and long-term cardiovascular outcome data is not yet available
Loss of lean mass alongside fat mass is a recognised issue across the incretin class and is not fully characterised for retatrutide
Weight regain after discontinuation has been documented across the class; durability data is limited
Counterfeit and unregulated material is widespread given the absence of an approved product

Evidence ratings

Laboratory studies

Strong

Receptor pharmacology thoroughly characterised.

Animal studies

Strong

Consistent superiority over dual agonism in rodent models.

Human studies

Moderate

Robust Phase 2 data; Phase 3 outcomes still accumulating.

Long-term safety

Limited

No published multi-year outcome or cardiovascular safety data.

Comparisons

Retatrutide vs Tirzepatide

Triple versus dual receptor agonism.

Mechanisms of action across the class

References

[1]Retatrutide Phase 2 obesity trial — PubMed / NEJM, 2023
[2]Retatrutide in type 2 diabetes — PubMed / The Lancet, 2023
[3]Registered retatrutide trials — ClinicalTrials.gov, current
[4]Triple agonist pharmacology reviews — PubMed, 2022–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is retatrutide?+

An investigational once-weekly peptide that activates the GIP, GLP-1 and glucagon receptors — described as a triple agonist.

Is retatrutide FDA approved?+

No. It remains investigational and is in Phase 3 trials; no regulator has approved it.

How much weight did retatrutide produce in trials?+

Phase 2 reported roughly 17.5% mean reduction at 24 weeks and about 24.2% at 48 weeks on the highest dose, compared with around 2% on placebo.

How does retatrutide differ from tirzepatide?+

Tirzepatide activates two receptors (GIP and GLP-1). Retatrutide adds glucagon receptor activity, which increases energy expenditure and hepatic fat oxidation.

What are the main side effects reported?+

Dose-related gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — plus observed increases in heart rate.

Why does adding glucagon not raise blood sugar?+

Glucagon does tend to raise glucose, but the GLP-1 and GIP components increase glucose-dependent insulin secretion, which offsets it at the ratios used.

Does retatrutide reduce liver fat?+

A Phase 2 study in participants with steatotic liver disease reported large reductions in liver fat content; confirmatory Phase 3 data is pending.

What happens after stopping?+

Weight regain following discontinuation is documented across the incretin class. Retatrutide-specific withdrawal data is limited.

Is muscle loss a concern?+

Loss of lean mass alongside fat mass is a recognised class issue. Body-composition data for retatrutide is not yet comprehensive.

When might retatrutide be approved?+

That depends on Phase 3 read-outs and regulatory review; no approval date can be stated with confidence.

Continue your research

Tirzepatide research

Semaglutide research

Incretin side effect research

Weight-loss hub